BioNTech, the German biotechnology company intimately associated with COVID-19 vaccines, is set to potentially transform its trajectory by pivoting into oncology, alongside current affairs related to its popular coronavirus vaccines. BioNTech, recognised for its work with Pfizer on the groundbreaking mRNA-based
COVID-19 vaccine, has also been taking strides in cancer care, with first launches expected in 2026. It had announced plans to commence mRNA vaccine production in Africa by 2025 after securing $145M funding to boost its mould-breaking mRNA technology. Yet, the company's stock remained volatile due to disappointing COVID-19 vaccine sales, and a net loss of €315.1M in Q1 2024. Creditors have also been looming, with BioNTech receiving a notice of default from the US NIH over unpaid royalties and enduring legal battles with Moderna and fellow Big Pharma firms who claim patent infringements. Now, BioNTech is delving deeper into its mRNA technology to create novel
cancer therapies. It has been forging partnerships for therapeutic collaborations and
R&D alliances. A case in point is their collaboration with Autolus for CAR-T therapies, and obtaining a promising response rate win against melanoma in a phase 2 trial with Regeneron.
BIONTECH News Analytics from Mon, 06 Nov 2023 08:00:00 GMT to Sun, 08 Sep 2024 13:48:31 GMT -
Rating -4
- Innovation 8
- Information 8
- Rumor 3
